← Back to headlines
Apellis Pharmaceuticals Stock Hits 2-Year High After Biogen Merger
Apellis Pharmaceuticals (APLS) stock has reached a two-year high, showing a 140% upside following its merger with Biogen.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
